PR Newswire
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
March 22, 2024
Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets RMB1.188 billion cash expected to support planned operations SHANGHAI and HONG KONG, March 22, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, c